The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma.
Rui-hua Xu
No relevant relationships to disclose
Guo-ping Sun
No relevant relationships to disclose
Hui-shan Lu
No relevant relationships to disclose
Liu Yun Peng
No relevant relationships to disclose
Jian-ming Xu
No relevant relationships to disclose
Mei-zuo Zhong
No relevant relationships to disclose
He-long Zhang
No relevant relationships to disclose
Shi-ying Yu
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Xiao-hua Hu
No relevant relationships to disclose
Jie Jun Wang
No relevant relationships to disclose
Ying Cheng
No relevant relationships to disclose
Jun-tian Zhou
No relevant relationships to disclose
Zeng-qing Guo
No relevant relationships to disclose
Zhongzhen Guan
No relevant relationships to disclose